# Hangzhou Ao Rui Biological Technology Co .

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-ao-rui-biological-technology-co

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.oriomics.com
- Total disclosed funding: $14M
- Latest round: Series B (Sep 11, 2023)
- Investors on record: 6

## About

Based in Hangzhou, China, and established in 2018, Hangzhou Ao Rui Biological Technology Co .,Ltd operates as a biotechnology company that focuses on technology development for non-invasive early screening and diagnosis of digestive system tumors. The core research team has over 30 employees and the company has many certifications, such as high-tech enterprise by Zhejiang province, and Hangzhou Double Hundred Plan. The company cooperates with more than 200 hospitals, such as Peking Union Medical College Hospital, Beijing People's Hospital and Tongji Hospital. In January 2021, it passed the high-tech enterprises and provincial high-tech enterprise R&D center certification. In September 2023, the company raised approximately CNY 100 million in series B+ funding led by Fortune Capital, with participation from Beijing Hotgen Biotech and Daoyuan Capital Management (Beijing).

The company is based on circulating tumor DNA (ctDNA) methylation assay and provides various single-cancer and multi-cancer screening products for patients with liver, stomach, intestines, esophagus and pancreas. Products include Liweian and Xiaoweian. Besides, it uses non-invasive blood-free DNA methylation testing technology and two-layer machine learning analytics algorithms for big data AI analytics to develop Oriomics-HRLB+ Oriomics-DLML. 

The company will invest in clinical registration and marketing of early liver cancer screening products and early GI multi-cancer screening products, and R&D of single-cancer and pan-cancer early screening and diagnostic products.

## Funding rounds

- Series B, Sep 11, 2023, $14M — Fortune Capital, Tao Capital, Beijing Hotgen Biotech
- Series A, Mar 6, 2018 — Legend Capital, Tianjin Venture Capital, K2VC

## Investors

- Legend Capital — Series A
- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Series A
- K2VC (https://capitalatlas.ai/funds/k2vc) — Series A
- Fortune Capital — Series B
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series B
- Beijing Hotgen Biotech — Series B